JBC Avanti Polar Lipids

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M200497200 on February 8, 2002

J. Biol. Chem., Vol. 277, Issue 17, 15028-15034, April 26, 2002
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/17/15028    most recent
M200497200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Asea, A.
Right arrow Articles by Calderwood, S. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Asea, A.
Right arrow Articles by Calderwood, S. K.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Novel Signal Transduction Pathway Utilized by Extracellular HSP70

ROLE OF Toll-LIKE RECEPTOR (TLR) 2 AND TLR4*

Alexzander AseaDagger , Michael Rehli§, Edith KabinguDagger , Jason A. Boch, Olivia BaréDagger , Philip E. Auron, Mary Ann Stevenson||, and Stuart K. CalderwoodDagger **

From the Dagger  Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, the § Department of Hematology and Oncology, University of Regensburg Medical Hospital, Regensburg 93042, Germany, the  Department of Medicine, Harvard Medical School and New England Baptist Bone and Joint Institute, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02115, and the || Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02115

Received for publication, January 16, 2002, and in revised form, February 6, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Recent studies have initiated a paradigm shift in the understanding of the function of heat shock proteins (HSP). It is now clear that HSP can and do exit mammalian cells, interact with cells of the immune system, and exert immunoregulatory effects. We recently demonstrated that exogenously added HSP70 possesses potent cytokine activity, with the ability to bind with high affinity to the plasma membrane, elicit a rapid intracellular Ca2+ flux, activate NF-kappa B, and up-regulate the expression of pro-inflammatory cytokines in human monocytes. Here for the first time, we report that HSP70-induced proinflammatory cytokine production is mediated via the MyD88/IRAK/NF-kappa B signal transduction pathway and that HSP70 utilizes both TLR2 (receptor for Gram-positive bacteria) and TLR4 (receptor for Gram-negative bacteria) to transduce its proinflammatory signal in a CD14-dependent fashion. These studies now pave the way for the development of highly effective pharmacological or molecular tools that will either up-regulate or suppress HSP70-induced functions in conditions where HSP70 effects are desirable (cancer) or disorders where HSP70 effects are undesirable (arthritis and arteriosclerosis).

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Innate immunity is the first line of host defense against infection and malignant transformation and has a profound effect on the establishment of adaptive immunity (1, 2). Cells of the innate immune system are adorned with recognition structures called pattern recognition receptors (2, 3). Pattern recognition receptors such as Toll-like receptors (TLRs),1 CD14, beta 2-integrins (CD11/CD18), complement receptors (CR1/CD35), and C-type lectins are expressed either as soluble proteins or plasma membrane-bound proteins that recognize invariant molecular structures called pathogen-associated molecular patterns (e.g. LPS, peptidoglycan, unmethylated CpG DNA, bacterial lipoprotein, and mannans of yeast), that are shared by numerous pathogens but are not normally expressed on host tissues (2). Recent studies on the recognition of microbial pathogen-associated molecular patterns have highlighted the central role played by one group of pattern recognition receptors, the TLR, in pathogen recognition and host defense (see review in Refs. 4-6). TLRs are similar in sequence and structure to the Drosophila Toll protein and they share a conserved extracellular leucine-rich region important for ligand binding. Both Toll and TLRs are type 1 transmembrane proteins whose intracellular signaling domains have a Toll/IL-lR homology motif (7-9). Toll was originally identified as an essential component of dorsal-ventral development in flies, and has since been linked to an immune response against fungal infection in adult flies (10, 11). The mammalian homologues of Toll also control innate immune responses through conserved signaling pathways. An adapter protein, MyD88, binds to a receptor Toll/IL-lR-domain through its own Toll/IL-lR motif, while a death domain on its C terminus recruits IL-1R-associated kinase (IRAK) to the complex. IRAK is then autophosphorylated, and released from the complex to bind TRAF6, which can then activate either the NF-kappa B pathway or the mitogen-activated protein kinase cascade (8). The TLR family is a fast growing family whose ligands have not all been identified. The most well characterized TLRs are TLR2 and TLR4. TLR4 initiates signaling cascades in response to lipopolysaccharide (LPS), the abundant glycolipid of the outer membrane of Gram-negative bacteria, Taxol, or HSP60, while TLR2 initiates the signal cascade in response to Gram-positive bacteria, Mycoplasma, Yeast, and Spirochetes.

Heat shock proteins (HSP) are highly conserved proteins found in all prokaryotes and eukaryotes. Under normal physiological conditions HSP are expressed at low levels (12). However, a wide variety of stressful stimuli including environmental (UV radiation, heat shock, heavy metals, and amino acids), pathological (viral, bacterial, parasitic infections or fever, inflammation, malignancy, or autoimmunity), or physiological stimuli (growth factors, cell differentiation, hormonal stimulation, or tissue development), induce a marked increase in intracellular HSP synthesis (13), known as the stress response. The primary function ascribed to HSP is as intracellular molecular chaperones of naïve, aberrantly folded, or mutated proteins as well as in cytoprotection following the kinds of stressful stimuli mentioned above. Recent findings showing that both HSP60 (14) and HSP70 (15, 16) can use CD14 to induce the generation of proinflammatory cytokines suggest that HSPs might represent a novel class of putative endogenous ligands for TLRs

In this report, we address the signal transduction cascade stimulated by exogenous HSP70 and reveal that HSP70-induced NF-kappa B promoter activity is MyD88-dependEnt, CD14-dependEnt, and is transduced via both TLR2 and TLR4. In addition, we show that TLR2 and TLR4 synergize to greatly augment HSP70-induced cytokine production. The physiological relevance of extracellular HSP70s ability to synergistically activate proinflammatory cytokine production helps elucidate recent findings indicating that HSP70 is a potent adjuvant for eliciting immune responses and a powerful inducer of anti-tumor immunity.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Isolation and Enrichment of Human DCS-- Peripheral blood mononuclear cells were isolated from freshly drawn peripheral venous blood (Kraft Family Blood Center, Dana-Farber Cancer Institute) using the Ficoll-Paque separation technique as described in detail elsewhere (17). Monocytes were enriched from the peripheral blood mononuclear cell fraction by negative depletion using magnetic beads coated with appropriate monoclonal antibodies. Briefly, using a monocyte isolation kit (Miltenyi Biotec, Aubum, CA), peripheral blood mononuclear cells were treated with FcR blocking agent followed by hapten-antibody mixture containing monoclonal hapten-conjugated CD3 (mouse Ig2A), CD7 (mouse Ig2A), CD19 (mouse IgG1), CD45RA (mouse IgG1), CD56 (mouse IgG2b), and anti-IgE (mouse IgG2A) antibodies and incubated for 5 min at 4 °C. Cells were washed twice in phosphate-buffered saline and incubated in FcR blocking buffer and MACs anti-hapten microbeads. After a 5-min incubation at 4 °C, cells were washed and passed through a column attached to a magnet. Unlabeled monocytes (CD45+CD14+) eluted from the column were >98% pure, as judged by flow cytometry. Cell viability was measured by Trypan blue exclusion. CD45+CD14+ monocytes were cultured for 8 days in RPMI (supplemented with 2 mM glutamine, 100 units/ml penicillin/streptomycin, and 1% autologous serum). To generate DC, cells were treated with granulocyte macrophage-colony stimulating factor (500 units/ml) and IL-4 (800 units/ml) on day 0. On day 4 of culture, granulocyte macrophage-colony stimulating factor was added to the cells.

Cell Lines and Tissue Culture Conditions-- HEK293 cells (ATCC, Rockville, MD) were maintained in Dulbecco's modified Eagle's medium (ATCC) supplemented with 10% fetal bovine serum, 100 units/ml penicillin G, 100 µg/ml streptomycin, and 2 mM L-glutamine, and 2% sodium bicarbonate. Cells were cultured at 37 °C in 5% CO2, 95% air humidified incubator. At ~70-90% confluence, cells were harvested using trypsin-EDTA, washed, and counted using a hemocytometer. Cells were grown in this fashion for no more than 10 passages.

Construction of Human Dominant Negative (DN) TLR2 and TLR4-- Mutations corresponding to the dominant negative TLR4 (P712H substitution) in C3H/HeJ-mice were introduced into hemaggultinin-tagged cDNAs of human TLR2 and TLR4 (kindly provided by Felix Randow) by PCR-directed mutagenesis, sequenced, and subcloned into the expression plasmid pRc/CMV (Invitrogen).

Transient Transfection of Cells and Measurement of Luciferase Activity-- Transient transfection of HEK293 (293 wild type), 293-TLR2, 293-TLR4, or 293-TLR2+4 cells was performed using FuGENE 6 (Roche Molecular Biochemicals) transfection reagent following the manufacturer's instructions. Briefly, cells were incubated with plasmids containing 1 µg of NF-kappa B reporter luciferase plasmid and, to correct for differences in transfection efficiency, each group of cells was transfected with 90 ng of pSV40/LACZ and co-transfected with either 1 µg of CD14 or 1 µg of TLR2DN or 1 µg of TLR4DN or 3 µg of MyD88DN or 3 µg of empty vector and incubated overnight. The ratio of luciferase activity to beta -galactosidase activity in each sample served as a measure of normalized luciferase activity. Following the various treatment protocols, cell extracts were prepared for determination of luciferase activity using enhanced luciferase assay reagents (Analytical Luminescence) according to the manufacturer's instructions. Luciferase assays were performed on a Monolight 2010 luminometer (Analytical Luminescence) for 20 s and results are expressed as the ratio of luciferase to beta -galactosidase and are the mean ± S.D. of experiments performed in triplicate and repeated at least three times.

Flow Cytometric Analysis-- Following treatment, 2 × 106 cells were simultaneously fixed and permeabilized using 2 ml of PermeaFix (OrthoDiagnostics, Raritan, NJ) for 40 min at room temperature in the dark, as previously described. Cells were then washed three times in phosphate-buffered saline. Nonspecific binding was inhibited by treating cells with 5.5% normal goat serum in phosphate-buffered saline for an additional 1 h at room temperature with gentle rocking. For the measurement of co-stimulatory molecule expression, cells were treated with anti-human CD86-alpha -PE or anti-human MHCII (1 µl/106 cells; BD PharMingen, Mountain View, CA) for 40 min at room temperature in the dark. Cells were then washed twice in phosphate-buffered saline and analyzed by flow cytometry. Flow cytometric analysis was performed on a FACScan with Lysis II software program (BD PharMingen). Individual cells were gated on the basis of forward (FSC) and orthogonal scatter (SSC). The photomultiplier for fluorescein isothiocyanate (FL1-height) or PE (FL2-height) was set on a logarithmic scale. Cell debris was excluded by raising the FSC-height PMT threshold. The flow rate was adjusted to <200 cells/s and at least 10,000 cells were analyzed for each sample.

Assay of Proliferation-- To determine the amount of proliferation, following the various treatment protocols the cells were pulsed with [3H]methylthymidine ([3H]TdR; specific activity 2 Ci/mol; PerkinElmer Life Science, Beverly, MA) for 8 h. When incubated with rapidly proliferating cells, [3H]TdR incorporates into the DNA. The amount of cellular incorporation of [3H]TdR is then estimated by liquid scintillography.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Exogenous HSP70 Activates NF-kappa B Promoter Activity-- We (15, 18) and others (16, 19) have recently shown that extracellular recombinant HSP70 (StressGen Biotechnologies; Victoria, BC, Canada) activates proinflammatory cytokine production by antigen presenting cells. Among the proinflammatory cytokines induced by HSP70 interaction with human monocytes, we identified IL-1beta , IL-6, and TNF-alpha (15, 18). IL-1beta has been shown to be produced following interaction at the surface membrane by complex formation between extracellular IL-1 and the transmembrane IL-1R type I (IL-1R1) and IL-1R accessory proteins (IL-1RAcP) (reviewed in Ref. 20). The resulting intracellular signaling cascade recruits two IRAK, IRAK1 and IRAK2, and an adapter protein MyD88 (21). Interestingly, IL-1 receptors (22, 23), IL-18 receptor (24-26), and TLRs (3, 27), signal through the MyD88/IRAK-NF-kappa B signal transduction pathway. To test whether recombinant HSP70-induced signaling cascade occurs via a similar pathway, THP1 monocytic cells were treated with various concentrations of HSP70 and NF-kappa B promoter activity was measured using a kappa B-luciferase reporter construct after 2 h incubation at 37 °C (Fig. 1). HSP70 dose dependently increased NF-kappa B promoter activity in THP1 monocytic cells (Fig. 1). Control protein OVA used at equimolar concentrations did not up-regulate NF-kappa B promoter activity significantly above background levels (Fig. 1). HSP70 at a concentration of 0.1 µg/ml resulted in submaximal activation of NF-kappa B promoter activity, and unless otherwise stated, was the concentration we used in subsequent experiments. Luciferase activity was observed at Hsp70 concentrations as low as 0.01 µg/ml (0.14 nM).


View larger version (13K):
[in this window]
[in a new window]
 
Fig. 1.   Dose response curve for extracellular HSP70-induced NF-kappa B activity. THP1 monocytic cells were stimulated with various concentrations of HSP70 (filled circles) or protein control, OVA (open circles), and incubated for 2 h at 37 °C after which extracts were prepared for determination of luciferase activity as described under "Experimental Procedures." Results are expressed as the ratio of luciferase (luc) to beta -galactosidase (beta -gal) and are the mean ± S.D. of four experiments performed in triplicate. *, p < 0.05 versus protein control, OVA (Student's t test).

Mechanism by Which HSP70 Activates NF-kappa B Promoter Activity: Role of CD14 and MyD88-- To determine the mechanism by which HSP70 activates the signal cascade that results in the activation of NF-kappa B promoter activity, we used HEK293 cells. HEK293 cells do not express IL-1R, CD14, or TLR. For these studies, we generated HEK293 cells that stably express IL-1R (293-IL-1R), TLR2 (293-TLR2), and TLR4 (293-TLR4). LPS (0.1 µg/ml) but not Hsp70 (0.1 µg/ml) activated NF-kappa B promoter activity in 293-TLR4 cells (Fig. 2). However, HSP70-induced NF-kappa B promoter activity was strongly restored in 293-TLR4 cells transiently transfected with CD14 to a level comparable with LPS-induced NF-kappa B promoter activation (Fig. 2). This is in line with our previous findings in which we demonstrated that HSP70 stimulates proinflammatory cytokine production in a CD14-dependant fashion (15). Transient transfection of 293-TLR4 cells with CD14 and the dominant negative MyD88 (MyD88DN) completely abrogated HSP70-induced and LPS-induced NF-kappa B promoter activity (Fig. 2). To rule out bacterial contamination of HSP70, we preincubated 293-TLR4 cells with Polymyxin B, a potent LPS inhibitor (28, 29). Preincubation of 293-TLR4 cells with Polymyxin B (10 µM) 30-60 min before activation abrogated LPS-induced but not HSP70-induced NF-kappa B promoter activity (Fig. 2). As an additional control, boiling HSP70 at 100 °C for 1 h completely abrogated HSP70-induced, but not LPS-induced NF-kappa B promoter activity (data not shown). Furthermore, HSP70 but not LPS induced a rapid intracellular Ca2+ flux in monocytes (15) (data not shown). Taken together, these results demonstrate that HSP70-induced NF-kappa B activity is dependant on CD14 to signal through TLR4, which initiates a signal cascade that is transduced via MyD88 (Fig. 2). As an additional control to demonstrate that HSP70-induced signaling specifically occurs through TLR4 and CD14, we used HEK293 cells stably transfected with IL-1R (293-IL-1R). We hypothesized that if the HSP70 signaling cascade is specific, HSP70 will not activate NF-kappa B promoter activity in 293-IL-1R. This is because, although both IL-1beta and TLR transduce signals via the Toll/IL-lR domain in a MyD88/IRAK/TRAF6-NF-kappa B signaling pathway, the external surface receptors for IL-1R and TLR are different. As expected, IL-1beta but not HSP70 activated NF-kappa B promoter activity in 293-IL-1R cells (Fig. 3). For additional specificity, IL-1beta -induced NF-kappa B promoter activity was abrogated in 293-IL1R cells transiently transfected with MyD88DN (Fig. 3). Taken together these results show that the external receptor for HSP70 is not the IL-1R and that extracellular HSP70 cannot directly interact with molecules downstream of TLR or IL-1R.


View larger version (14K):
[in this window]
[in a new window]
 
Fig. 2.   CD14 and TLR are required for optimum activation of NF-kappa B by extracellular HSP70. HEK293-TLR4 cells were transfected with 1 µg of NF-kappa B reporter luciferase plasmid alone or co-transfected with 3 µg of MyD88DN or CD14 or empty vector. Cells were preincubated with or without Polymyxin B (10 mM) then stimulated with 0.1 µg/ml HSP70 (filled bars) or 0.1 µg/ml LPS (gray bars) or 0.1 µg/ml OVA (open bars) and incubated for 2 h after which extracts were prepared for determination of luciferase activity. Bars represent the ratio of luciferase (luc) to beta -galactosidase (beta -gal) and are the mean ± S.D. of three experiments performed in triplicate. *, p < 0.05 versus protein control, OVA (Student's t test).


View larger version (11K):
[in this window]
[in a new window]
 
Fig. 3.   Extracellular HSP70 does not signal through IL-1R. HEK293 wild type (open bars) or HEK293-IL-1R cells (filled bars) were transfected with 1 µg of IL-1 reporter luciferase plasmid alone or co-transfected with 3 µg of MyD88DN or CD14 or empty vector. Cells were stimulated with 0.1 µg/ml HSP70 or IL-1beta and incubated for 2 h after which extracts were prepared for determination of luciferase activity. Bars represent the ratio of luciferase (luc) to beta -galactosidase (beta -gal) and are the mean ± S.D. of two experiments performed in triplicate. *, p < 0.05 versus respective controls (Student's t test).

Signaling Intermediates in HSP70-induced NF-kappa B Activation: Role of TLRs-- We also examined a possible role of TLR2 in extracellular HSP70-mediated signaling. To our surprise, stimulation of 293-TLR2 cells co-transfected with CD14 with HSP70 (0.1 µg/ml) induced potent NF-kappa B promoter activity to a level equivalent to 293-TLR4 cells co-transfected with CD14 (Fig. 4). To confirm that HSP70 was indeed signaling through TLR2 and CD14, we pretreated 293-TLR2 cells with anti-TLR2 before stimulation with HSP70. Pretreatment of 293-TLR2 cells with anti-TLR2 completely abrogated HSP70-induced NF-kappa B promoter activity in HEK293-TLR2, but not HEK293-TLR4 cells (Fig. 4). We then asked the question as to what kind of signaling would occur if both TLR2 and TLR4 were expressed on the surface of HEK293 cells. Therefore, HEK293 cells were generated that stably expressed both TLR2 and TLR4 (293-TLR2+4). Treatment of 293-TLR2+4 with HSP70 resulted in the synergistic activation of NF-kappa B promoter activity in a CD14-dependant fashion (Fig. 5). The HSP70-induced NF-kappa B promoter activity was only partially inhibited by co-transfection of 293-TLR2+4 with dominant negative TLR2 (TLR2DN) or dominant negative TLR4 (TLR4DN) (Fig. 5). Co-transfection of 293-TLR2+4 with both TLR2DN and TLR4DN completely abrogated HSP70-induced CD14-dependent NF-kappa B promoter activity (Fig. 5). On the other hand, co-transfection of 293-TLR2+4 with CD14 plus MyD88DN only partially inhibited HSP70-induced NF-kappa B promoter activity (Fig. 6). It has recently been suggested that although TLR4 might act as a homodimer, TLR2 cannot form functional homodimers and acts only in combination with selected TLR proteins, forming heterodimers with, for example, TLR1 and TLR6 (30). Taken together, these results suggest that a combination of TLR2 and TLR4 plus CD14 triggers HSP70-induced MyD88-independent signaling and implies that TRL2 can form functional homodimers as well as functional heterodimers with TLR4 for HSP70-induced signaling.


View larger version (13K):
[in this window]
[in a new window]
 
Fig. 4.   HSP70-induced signal cascade utilizes both TLR2 and TLR4 to activate NF-kappa B activity. HEK293 wild type cells (open bars) or HEK293-TLR2 cells (gray bars) or HEK293-TLR4 cells (filled bars) were transfected with 1 µg of NF-kappa B reporter luciferase plasmid alone or co-transfected with 3 µg of CD14 or empty vector. Cells pretreated with anti-TLR2 for 30 min before stimulation with 0.1 µg/ml HSP70 or 0.1 µg/ml OVA and incubated for 2 h after which extracts were prepared for determination of luciferase activity. Bars represent the ratio of luciferase (luc) to beta -galactosidase (beta -gal) and are the mean ± S.D. of three experiments performed in triplicate. *, p < 0.05 versus respective controls (Student's t test).


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 5.   Exogenous HSP70 synergistically augments NF-kappa B promoter activity in HEK293 cells expressing both TLR2 and TLR4. HEK293 wild type (open bars), HEK293-TLR2 cells (left hatched bars), HEK293-TLR4 cells (right hatched bars), or HEK293-TLR2+4 cells (filled bars) were transfected with 1 µg of NF-kappa B reporter luciferase plasmid alone or co-transfected with 3 µg of CD14 or TLR2DN or TLR4DN or TLR2DN + TLR4DN or empty vector. Cells were stimulated with 0.1 µg/ml HSP70 or 0.1 µg/ml OVA and incubated for 2 h after which extracts were prepared for determination of luciferase activity. Bars represent the ratio of luciferase (luc) to beta -galactosidase (beta -gal) and are the mean ± S.D. of four experiments performed in triplicate. *, p < 0.05 versus respective controls (Student's t test).


View larger version (14K):
[in this window]
[in a new window]
 
Fig. 6.   Synergistic activation of NF-kappa B promoter by co-expression of both TLR2 and TLR4 on HEK293 cells is MyD88-independent. HEK293-TLR2 cells (open bars), HEK293-TLR4 cells (gray bars), or HEK293-TLR2+4 cells (filled bars) were transfected with 1 µg of NF-kappa B reporter luciferase plasmid alone or co-transfected with 3 µg of CD14 or MyD88DN or TLR2DN + TLR4DN or empty vector. Cells were stimulated with 0.1 µg/ml HSP70 or OVA and incubated for 2 h after which extracts were prepared for determination of luciferase activity. Bars represent the ratio of luciferase (luc) to beta -galactosidase (beta -gal) and are the mean ± S.D. of three experiments performed in triplicate. *, p < 0.05 versus respective controls (Student's t test).

Biological Significance of HSP70-induced NF-kappa B Activity: Linking Innate and Adaptive Immunity-- The functional consequence of the interaction between extracellular HSP70 and human monocytes has recently been investigated. We (15, 18) and others (16) have recently demonstrated that extracellular HSP70 induces potent cytokine production in human monocytes via interaction with CD14. These findings suggest that HSPs may not only serve as a vehicle for antigenic peptides but also as a "danger signal" to the innate and specific immune system as suggested for other endogenous activators of antigen presenting cells (31). Once activated, mature antigen presenting cells display their full co-stimulatory potential and are able to communicate very effectively with naive T-helper lymphocytes and prime cytotoxic T lymphocytes to mount potent and effective adaptive immune responses. Therefore, we investigated whether HSP70 was able to deliver a maturation signal to DCs. Human DCs were generated in vitro from peripheral blood mononuclear cells obtained from freshly drawn peripheral venous blood and incubated with granulocyte macrophage-colony stimulating factor as previously described (32). Treatment of human DCs with HSP70 and LPS augmented pro-inflammatory cytokine, IL-1beta , IL-12, and TNF-alpha production, as determined by enzyme-linked immunosorbent assay (Table I). To exclude the possibility that this effect was due to contamination of the protein preparation by endotoxins such as LPS, boiling (100 °C, 1 h) HSP70 abrogated cytokine production, whereas LPS-induced cytokine production was not significantly abrogated by boiling (Table I). The ability of antigen presenting cells to induce an immune response depends both on the regulated expression of cytokines, which act directly on T lymphocytes and on the up-regulation of co-stimulatory molecules on DCs (32, 33). In line with these findings, intact HSP70 and LPS, but not boiled HSP70, up-regulated the expression of co-stimulatory molecules CD86 (B7.2) and myosin heavy chain class II on human DCs, as determined by flow cytometric analysis (Table I). Treatment of irradiated immature DCs with HSP70 resulted in augmentation in proliferation of T lymphocytes 7-8-fold greater than in T lymphocytes incubated with irradiated immature DCs treated with either boiled HSP70 or control protein OVA, as determined after 5 days by incorporation of [3H]TdR (data not shown). Proliferation of mature DCs was significantly lower as compared with immature DCs in response to stimulation with intact HSP70 and LPS or boiled LPS (Table I). This is in agreement with previous data showing that activated mature DCs grow slower than non-activated immature DCs (Table I). Treatment of DCs with boiled HSP70 did not result in significant proliferation above control levels (Table I). The ability of HSP70 to induce cytokine and co-stimulatory molecule expression on DCs suggests that it might play an important role in linking innate and adaptive immune responses.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Chaperokine effect of extracellular HSP70: induction of cytokine production, co-stimulatory molecule expression and proliferation of DCs

To further demonstrate that CD14, TLR2, and TLR4 are required for potent HSP70-induced cytokine production, we grew HEK293 cells on culture slides. The cells were then transfected with CD14 alone or CD14 + TLR2 or CD14 + TLR2 + TLR4 followed by stimulation with equimolar amounts (0.1 µg/ml) of HSP70 or control protein OVA for 4 h at 37 °C, stained with IL-6-fluorescein isothiocyanate, mounted with a 4,6-diamidino-2-phenylindole-based mounting media, and analyzed using fluorescence microscope (Fig. 7A). In accordance with the luciferase data, HEK293 cells transfected with CD14 + TLR2 and stimulated with HSP70 but not control protein OVA, resulted in enhanced intracellular IL-6 production (Fig. 7A). As expected, HEK293 cells transfected with CD14 + TLR2 + TLR4, when stimulated with HSP70 but not control protein OVA, resulted in potent augmentation of intracellular IL-6 production, which was far in excess to that of HSP70 stimulated HEK293 cells transfected with CD14 + TLR2 (Fig. 7A) or CD14 + TLR4 (data not shown). Extracellular HSP70 was not effective at stimulating intracellular IL-6 production from HEK293 cells transiently transfected with either TLR vector alone or CD14 alone (Fig. 7A). The phase-contrast images show the total number of cells that were present at the time of the experiment (Fig. 7B).


View larger version (35K):
[in this window]
[in a new window]
 
Fig. 7.   CD14, TLR2, and TLR4 are required for potent HSP70-induced IL-6 production. HEK293 cells were grown on Falcon culture slides (BD Labware, Franklin Lakes, NJ) overnight and then co-transfected for 24 h with vector alone or CD14 or CD14 + TLR2 or CD14 + TLR2 + TLR4. Cells were then stimulated with 100 ng/ml HSP70 (right panels) or control (100 ng/ml OVA; left panels) at 37 °C for 4 h in the presence of 10 mM brefeldin A (Sigma). After this cells were simultaneously fixed and permeabilized using the Cytofix/CytopermTM kit (BD Biosciences, San Diego, CA) according to the manufacturer's instructions and counterstained with anti-human IL-6-fluorescein isothiocyanate (BD Biosciences). One drop of mounting media containing 4,6-diamidino-2-phenylindole stain to visualize nuclear staining (Oncogene, Boston, MA) was placed onto the glass slide before the coverslip was sealed with nail polish. Results are a representative of four independently performed with similar results. Results show (A) fluorescence image showing nuclear morphology (blue) and intracellular IL-6 production (green), and (B) phase-contrast image of all cells on the culture slide. Results are a representative of two independently performed experiments with similar results.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

This report for the first time demonstrates that HSP70-induced proinflammatory cytokine production is mediated via the MyD88/NF-kappa B signal transduction pathway and that HSP70 utilizes both TLR2 (receptor for Gram-positive bacteria) and TLR4 (receptor for Gram-negative bacteria) to transduce its proinflammatory signal in a CD14-dependent fashion. The biological significance of these findings now pave the way for the development of highly effective pharmacological or molecular tools that will either up-regulate or suppress HSP70-induced functions in conditions where HSP70 effects are desirable or disorders where HSP70 effects are undesirable.

A major concern of these studies was to ascertain that our HSP70-induced effects were not being masked by endotoxin contamination. We show that boiling (100 °C, 1 h) abrogated HSP70 but not LPS-induced effects (Table I). In addition, pretreatment with LPS antagonist, Polymyxin B abrogated LPS but not HSP70 effects (Fig. 2). We also performed the Limulus lysate assay (BioWhittaker) on every HSP70 sample and all reagents and culture media used in the experiments to ensure that LPS contamination was always below 5 pg/ml. Taken together, these results demonstrate that the effect of HSP70 are thus genuine properties of HSP70 rather than due to endotoxin contamination.

The requirement for CD14 in HSP70-induced signaling via TLR is in line with our previous findings that CD14 is a co-receptor for HSP70-induced proinflammatory cytokine production in human monocytes (15). It has been known that host recognition of microbial products like LPS, peptidoglycan, and bacterial lipoprotein is principally mediated by either a membrane-bound or by a soluble form of the glycoprotein, CD14 (for review, see Refs. 34 and 35). Ligation of microbial products to CD14 triggers the production of proinflammatory cytokines. However, CD14 is a gylcosylphosphatidylinositol-anchored membrane protein, devoid of an intracellular domain (36). The mechanism by which CD14 transmits signals was until recently unknown. Studies of mammalian TLRs have now provided intriguing evidence that TLRs are the CD14-associated signal transducers for different classes of microbial products. Here we show that CD14 is required for optimal HSP70-induced signaling via TLR2 and TLR4 (Fig. 4). This is unique since HSP60 (14) and LPS (34) have recently been shown to utilize only TLR4 and CD14 for signaling that results in the induction of proinflammatory cytokines (14).

Ozinsky and co-workers (37) have recently shown that both TLR2 and TLR6 are required for macrophage-mediated TNF-alpha production in response to yeast and Gram-positive bacterial products, but not Gram-negative bacteria. These findings suggest that TLR proteins might act as dimers and in some cases as heterodimers. Indeed, it was suggested that TLR4 might behave as a homodimer, whereas TLR2 cannot form functional homodimers and acts only in combination with selected TLR proteins, like TLR1 and TLR6 (for review, see Refs. 30). In this report, we show that HSP70 can interact with both TLR2 and TLR4 in a CD14-dependent fashion, and that this combination is particularly effective resulting in the synergistic activation of NF-kappa B activity (Figs. 5 and 6). The significance of these findings suggest how a restricted family of receptors, like the TLR family, is able to discriminate between the wide spectrum of TLR stimuli that is known to exist. Extensive insight into the complex nature in which DCs discriminate different pathogens (Escherichia coli, Candida albicans, and influenza virus) at a genetic level has recently been initiated using a novel DNA microarray method that reveals the genome-wide location of DNA-bound proteins (38, 39). In another report, it was recently shown that LPS activates cytokine production via a MyD88-dependent pathway and activates co-stimulatory molecule expression via a MyD88-independent pathway (40). Experiments showing that HSP70-induced NF-kappa B promoter activity is only partially inhibited by MyD88DN in HEK293 cells co-expressing both TLR2 and TLR4 (Fig. 6), suggest that under certain conditions HSP70 might signal by both a MyD88-dependent and MyD88-independent signal transduction pathway. To conclusively answer this question experiments are now underway to test HSP70-induced cytokine and co-stimulatory molecule expression in primary cultures of human DC after transient transfection with MyD88DN, TLR2DN, and/or TLR4DN. At the submission of this report, a novel adaptor protein was described known as MyD88-adaptor-like and shown to be an adaptor for TLR4 signaling (41). In addition, MyD88-adaptor-like was demonstrated to abrogate TLR4, but not IL-1 or IL-18-induced signaling (41). If confirmed, studies into the role of MyD88-adaptor-like in HSP70-induced signaling could provide useful information on how extracellular HSP70 mediates its proinflammatory and anti-tumor effects.

The biological significance and diversity of responses attributed to HSP70 is remarkable. The term chaperokine has recently been coined to better describe the ability of HSP70 to act as a chaperone and cytokine (15, 18). In addition to functioning as an antigen carrier, HSP70 coupled to peptides has recently been shown to induce cytokine production (42). Furthermore, a recombinant HIV p24-HSP70 fusion protein elicits both humoral and cellular immune responses against p24 in mice (43), and tumor-derived HSP70 is taken up by immature DCs and causes production of TH1 cytokines such as IFN-gamma , TNF-alpha , and IL-12 (44). In this report, we demonstrate that the effects observed in vitro are applicable to the biological system. Thus, experiments with HEK293 cells confirmed that TLR2 and TLR4 work synergistically to potently augment intracellular IL-6 production in response to HSP70 stimulation (Fig. 7A). This demonstrates the specificity of the HSP70-induced signaling pathway and its dependence on TLR and the MyD88/NF-kappa B signal transduction pathway.

This report demonstrates for the first time that HSP70-induced proinflammatory cytokine production is mediated via the MyD88/NF-kappa B signal transduction pathway and that HSP70 utilizes both TLR2 (receptor for Gram-positive bacteria) and TLR4 (receptor for Gram-negative bacteria) to transduce its proinflammatory signal in a CD14-dependent fashion. These findings now pave the way for the development of highly effective pharmacological or molecular tools that will either up-regulate or suppress HSP70-induced functions in conditions where HSP70 effects are desirable or disorders where HSP70 effects are undesirable.

    ACKNOWLEDGEMENTS

We thank Rajani Mallick and Rahilya Napoli for expert technical assistance, The Kraft Family Blood Center, Dana-Farber Cancer Institute for the freshly drawn peripheral venous blood, Dr. Jay Harris for departmental support, and Yasuhiro Yoshida and Yoshinobu Koyama for preparation of the MyD88DN and TLR4DN and the stable HEK293 IL-1RI expressing cell lines.

    FOOTNOTES

* This work was supported by National Institutes of Health Grants CA47407, CA31303, CA50642, and CA77465 (to S. K. C.), a Joint Center for Radiation Therapy Foundation Grant (to A. A.), National Institutes of Health Grants CA68544 and AI44122 (to P. E. A.) and the Deutsche Forschungsgemeinschaft (to M. R.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

** To whom correspondence may be addressed: Dept. of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 44 Binney St. (D810), Boston, MA 02115. Tel.: 617-632-3885; Fax: 617-632-4599; E-mail: stuart_calderwood@dfci.harvard.edu.

Published, JBC Papers in Press, February 8, 2002, DOI 10.1074/jbc.M200497200

    ABBREVIATIONS

The abbreviations used are: TLR, Toll-like receptor; IRAK, IL-1R-associated kinase; LPS, lipopolysaccharide; HSP, heat shock protein; IL, interleukin; DN, dominant negative; TNF-alpha , tumor necrosis factor-alpha ; [3H]TdR, [3H]methylthymidine; OVA, ovalbumin; DC, dendritic cell.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Fearon, D. T., and Locksley, R. M. (1996) Science 272, 50-53[Abstract]
2. Medzhitov, R., and Janeway, C. A. J. (1997) Curr. Opin. Immunol. 9, 4-9[CrossRef][Medline] [Order article via Infotrieve]
3. Medzhitov, R., Preston-Hurlburt, P., and Janeway, C. A., Jr. (1997) Nature 388, 394-397[CrossRef][Medline] [Order article via Infotrieve]
4. Anderson, K. V. (2000) Curr. Opin. Immunol. 12, 13-19[CrossRef][Medline] [Order article via Infotrieve]
5. Janeway, C. A. J. (1999) Curr. Biol. 9, R879-R882[CrossRef][Medline] [Order article via Infotrieve]
6. Zhang, G., and Ghosh, S. (2001) J. Clin. Invest. 107, 13-19[Medline] [Order article via Infotrieve]
7. Aderem, A., and Ulevitch, R. J. (2000) Nature 406, 782-787[CrossRef][Medline] [Order article via Infotrieve]
8. Kopp, E. B., and Medzhitov, R. (1999) Curr. Opin. Immunol. 11, 13-18[CrossRef][Medline] [Order article via Infotrieve]
9. Rock, F. L., Hardiman, G., Timans, J. C., Kastelein, R. A., and Bazan, J. F. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 588-593[Abstract/Free Full Text]
10. Lemaitre, B., Nicolas, E., Michaut, L., Reichhart, J. M., and Hoffmann, J. A. (1996) Cell 86, 973-983[CrossRef][Medline] [Order article via Infotrieve]
11. Muzio, M., and Mantovani, A. (2000) Microbes Infect. 2, 251-255[CrossRef][Medline] [Order article via Infotrieve]
12. Craig, E. A., and Gross, C. A. (1991) Trends Biochem. Sci. 16, 135-140[CrossRef][Medline] [Order article via Infotrieve]
13. Lindquist, S., and Craig, E. A. (1988) Annu. Rev. Genet. 22, 631-677[CrossRef][Medline] [Order article via Infotrieve]
14. Ohashi, K., Burkart, V., Flohe, S., and Kolb, H. (2000) J. Immunol. 164, 558-561[Abstract/Free Full Text]
15. Asea, A., Kraeft, S. K., Kurt-Jones, E. A., Stevenson, M. A., Chen, L. B., Finberg, R. W., Koo, G. C., and Calderwood, S. K. (2000) Nat. Med. 6, 435-442[CrossRef][Medline] [Order article via Infotrieve]
16. Moroi, Y., Mayhew, M., Trcka, J., Hoe, M. H., Takechi, Y., Hartl, F. U., Rothman, J. E., and Houghton, A. N. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 3485-3490[Abstract/Free Full Text]
17. Asea, A. (1995) The Role of Histamine in the Regulation of Natural Killer Cells Doctoral dissertation , University of Göteborg, Göteborg, Sweden, 1-88
18. Asea, A., Kabingu, E., Stevenson, M. A., and Calderwood, S. K. (2000) Cell Stress Chaperones 5, 425-431[CrossRef][Medline] [Order article via Infotrieve]
19. Binder, R. J., Harris, M. L., Menoret, A., and Srivastava, P. K. (2000) J. Immunol. 165, 2582-2587[Abstract/Free Full Text]
20. Auron, P. E. (1998) Cytokine Growth Factor Rev. 9, 221-237[CrossRef][Medline] [Order article via Infotrieve]
21. Jensen, L. E., Muzio, M., Mantovani, A., and Whitehead, A. S. (2000) J. Immunol. 164, 5277-5286[Abstract/Free Full Text]
22. Wesche, H., Henzel, W. J., Shillinglaw, W., Li, S., and Cao, Z. (1997) Immunity 7, 837-847[CrossRef][Medline] [Order article via Infotrieve]
23. Muzio, M., Ni, J., Feng, P., and Dixit, V. M. (1997) Science 278, 1612-1615[Abstract/Free Full Text]
24. Kanakaraj, P., Ngo, K., Wu, Y., Angulo, A., Ghazal, P., Harris, C. A., Siekierka, J. J., Peterson, P. A., and Fung-Leung, W. P. (1999) J. Exp. Med. 189, 1129-1138[Abstract/Free Full Text]
25. Adachi, O., Kawai, T., Takeda, K., Matsumoto, M., Tsutsui, H., Sakagami, M., Nakanishi, K., and Akira, S. (1998) Immunity 9, 143-150[CrossRef][Medline] [Order article via Infotrieve]
26. Thomassen, E., Bird, T. A., Renshaw, B. R., Kennedy, M. K., and Sims, J. E. (1998) J. Interferon Cytokine Res. 18, 1077-1088[Medline] [Order article via Infotrieve]
27. Medzhitov, R., Preston-Hurlburt, P., Kopp, E., Stadlen, A., Chen, C., Ghosh, S., and Janeway, C. A., Jr. (1998) Mol. Cell 2, 253-258[CrossRef][Medline] [Order article via Infotrieve]
28. Golenbock, D. T., Hampton, R. Y., Qureshi, N., Takayama, K., and Raetz, C. R. (1991) J. Biol. Chem. 266, 19490-19498[Abstract/Free Full Text]
29. Duff, G. W., and Atkins, E. (1982) J. Immunol. Methods 52, 333-340[CrossRef][Medline] [Order article via Infotrieve]
30. Heldwein, K. A., Goldenbock, D. T., and Fenton, M. J. (2001) Mod. Asp. Immunobiol. 1, 249-252
31. Matzinger, P. (1998) Semin. Immunol. 10, 399-415[CrossRef][Medline] [Order article via Infotrieve]
32. Inaba, K., Witmer-Pack, M., Inaba, M., Hathcock, K. S., Sakuta, H., Azuma, M., Yagita, H., Okumura, K., Linsley, P. S., Ikehara, S., Muramatsu, S., Hodes, R. J., and Steinman, R. M. (1994) J. Exp. Med. 180, 1849-1860[Abstract/Free Full Text]
33. Hathcock, K. S., Laszlo, G., Pucillo, C., Linsley, P., and Hodes, R. J. (1994) J. Exp. Med. 180, 631-640[Abstract/Free Full Text]
34. Fenton, M. J., and Goldenbock, D. T. (1998) J. Leukocyte Biol. 64, 25-32[Abstract]
35. Ulevitch, R. J., and Tobias, P. S. (1995) Annu. Rev. Immunol. 13, 437-457[CrossRef][Medline] [Order article via Infotrieve]
36. Ulevitch, R. J., and Tobias, P. S. (1994) Curr. Opin. Immunol. 6, 125-130[CrossRef][Medline] [Order article via Infotrieve]
37. Ozinsky, A., Underhill, D. M., Fontenot, J. D., Hajjar, A. M., Smith, K. D., Wilson, C. B., Schroeder, L., and Aderem, A. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 13766-13771[Abstract/Free Full Text]
38. Huang, Q., Liu do, N., Majewski, P., Schulte le, A. C., Korn, J. M., Young, R. A., Lander, E. S., and Hacohen, N. (2001) Science 294, 870-875[Abstract/Free Full Text]
39. Ren, B., Robert, F., Wyrick, J. J., Aparicio, O., Jennings, E. G., Simon, I., Zeitlinger, J., Schreiber, J., Hannett, N., Kanin, E., Volkert, T. L., Wilson, C. J., Bell, S. P., and Young, R. A. (2000) Science 290, 2306-2309[Abstract/Free Full Text]
40. Kaisho, T., and Akira, S. (2001) Trends Immunol. 22, 78-83[CrossRef][Medline] [Order article via Infotrieve]
41. Fitzgerald, K. A., Palsson-McDermott, E. M., Bowie, A. G., Jefferies, C. A., Mansell, A. S., Brady, G., Brint, E., Dunne, A., Gray, P., Harte, M. T., McMurray, D., Smith, D. E., Sims, J. E., Bird, T. A., and O'Neill, L. A. (2001) Nature 413, 78-83[CrossRef][Medline] [Order article via Infotrieve]
42. Moseley, P. (2000) Immunopharmacology 48, 299-302[CrossRef][Medline] [Order article via Infotrieve]
43. Suzue, K., and Young, R. A. (1996) J. Immunol. 156, 873-879[Abstract]
44. Todryk, S., Melcher, A. A., Hardwick, N., Linardakis, E., Bateman, A., Colombo, M. P., Stoppacciaro, A., and Vile, R. G. (1999) J. Immunol. 163, 1398-1408[Abstract/Free Full Text]


Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Hum ReprodHome page
K. N. Khan, M. Kitajima, T. Imamura, K. Hiraki, A. Fujishita, I. Sekine, T. Ishimaru, and H. Masuzaki
Toll-like receptor 4-mediated growth of endometriosis by human heat-shock protein 70
Hum. Reprod., October 1, 2008; 23(10): 2210 - 2219.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
E. Galloway, T. Shin, N. Huber, T. Eismann, S. Kuboki, R. Schuster, J. Blanchard, H. R. Wong, and A. B. Lentsch
Activation of hepatocytes by extracellular heat shock protein 72
Am J Physiol Cell Physiol, August 1, 2008; 295(2): C514 - C520.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
K. Rayner, Y.-X. Chen, M. McNulty, T. Simard, X. Zhao, D. J. Wells, J. de Belleroche, and E. R. O'Brien
Extracellular Release of the Atheroprotective Heat Shock Protein 27 Is Mediated by Estrogen and Competitively Inhibits acLDL Binding to Scavenger Receptor-A
Circ. Res., July 18, 2008; 103(2): 133 - 141.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
B. Valentinis, A. Capobianco, F. Esposito, A. Bianchi, P. Rovere-Querini, A. A. Manfredi, and C. Traversari
Human recombinant heat shock protein 70 affects the maturation pathways of dendritic cells in vitro and has an in vivo adjuvant activity
J. Leukoc. Biol., July 1, 2008; 84(1): 199 - 206.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
N. Zou, L. Ao, J. C. Cleveland Jr., X. Yang, X. Su, G.-Y. Cai, A. Banerjee, D. A. Fullerton, and X. Meng
Critical role of extracellular heat shock cognate protein 70 in the myocardial inflammatory response and cardiac dysfunction after global ischemia-reperfusion
Am J Physiol Heart Circ Physiol, June 1, 2008; 294(6): H2805 - H2813.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
J. Cha, Z. Wang, L. Ao, N. Zou, C. A. Dinarello, A. Banerjee, D. A. Fullerton, and X. Meng
Cytokines link toll-like receptor 4 signaling to cardiac dysfunction after global myocardial ischemia.
Ann. Thorac. Surg., May 1,&nbs